Prosecution Insights
Last updated: November 04, 2026
Application No. 18/853,512

CATIONIC LIPID, LIPOSOME, LIPID NANOPARTICLE, AND USE

Non-Final OA §102§103
Filed
Oct 02, 2024
Priority
Apr 02, 2022 — CN 202210349570.6 +1 more
Examiner
PACKARD, BENJAMIN J
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Arivia Biotechnology (Shanghai) Co. Ltd.
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
10m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
908 granted / 1356 resolved
+7.0% vs TC avg
Strong +15% interview lift
Without
With
+15.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
53 currently pending
Career history
1417
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
48.2%
+8.2% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
15.8%
-24.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1356 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Election/Restrictions Applicants’ election without traverse of Example 4, CPL-092-01 n the reply filed on 08/28/2026 is acknowledged. Claims 7, 8, 10, and 11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected species, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. While the species election has not been expanded, the following rejection is presented to further compact prosecution insofar as reference is anticipatory to the broader claims. Claims 1-6, 9, 12, 14-15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ying (WO2021204175). Disclose the compound 85-4 (pg 169): PNG media_image1.png 284 736 media_image1.png Greyscale which reads on the instant claims where A is nitrile, B is C2 alkyl substituted with Rd, Rd is hydroxy, L3 and L4 are both C5 alkylene, Y2 is -OC(=O)-, L4 is C4 alkyl, and R4 and R5 are both C4 alkyl. The C chain is the same as the D chain. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-6, 9, and 12-15 are rejected under 35 U.S.C. 103 as being unpatentable over Ying (WO2021204175). Ying is discussed above, but the alkyl chains are not the same as the elected species. Ying further teaches the broad class of compounds of formula (I) (¶¶ 101-109 and claim 1): PNG media_image2.png 160 212 media_image2.png Greyscale where G1 and G2 are each independently C2-C12 alkylene, G3 is C2-C24 alkylene, and R1 and R2 are each independently C6-C32alkyl. It would have been obvious to formulate compound 85 having variable length alkyl chains within the disclosed ranges. In doing so, the intermediate compound would have chains of the same length, resulting in the development of a compound with the alkyl chain lengths the same as the instantly elected species. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BENJAMIN J PACKARD whose telephone number is (571)270-3440. The examiner can normally be reached Mon 2-6pm and Tues-Fri 9:30am-6:30pm + mid-day flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BENJAMIN J PACKARD/ Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Oct 02, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778174
COMPOSITIONS FOR USE IN THE REDUCTION OF NOCICEPTION AND OTHER HEALTH BENEFITS IN INFANTS AND YOUNG CHILDREN
4y 4m to grant Granted Nov 03, 2026
Patent 12782339
SYNTHESIS AND USE OF N-BENZYL SULFONAMIDES
3y 9m to grant Granted Nov 03, 2026
Patent 12779056
AGENT FOR DETECTING INTERACTION BETWEEN TISSUES AND ORGANS
3y 6m to grant Granted Nov 03, 2026
Patent 12778862
STABLE BIOACTIVE GLASS FORMULATIONS
2y 6m to grant Granted Nov 03, 2026
Patent 12778892
RADIOPROTECTIVE COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
1y 12m to grant Granted Nov 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
82%
With Interview (+15.3%)
2y 11m (~10m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1356 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month